Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Uwe Platzbecker(University Hospital Leipzig), Jan Moritz Middeke(German Cancer Research Center), Katja Sockel(German Cancer Research Center), Regina Herbst(Klinikum Chemnitz), Dominik Wolf(Innsbruck Medical University), Claudia D. Baldus(Charité - Universitätsmedizin Berlin), Uta Oelschlägel(National Center for Tumor Diseases), Anke Mütherig(National Center for Tumor Diseases), Lars Fransecky(Charité - Universitätsmedizin Berlin), Richard Noppeney(Essen University Hospital), Gesine Bug(German Cancer Research Center), Katharina S. Götze(Technical University of Munich), Alwin Krämer(Heidelberg University), Tilmann Bochtler(Heidelberg University), Matthias Stelljes(University Hospital Münster), Christoph Groth(University Hospital Münster), Antje Schubert(German Cancer Research Center), Marika Mende(National Center for Tumor Diseases), Friedrich Stölzel(German Cancer Research Center), Christine Borkmann(National Center for Tumor Diseases), Anne Sophie Kubasch(National Center for Tumor Diseases), Malte von Bonin(German Cancer Research Center), Hubert Serve(Goethe University Frankfurt), Mathias Hänel(Klinikum Chemnitz), Ulrich Dührsen(Essen University Hospital), Johannes Schetelig(German Cancer Research Center), Christoph Röllig(National Center for Tumor Diseases), Michael Krämer(German Cancer Research Center), Gerhard Ehninger(National Center for Tumor Diseases), Martin Bornhäuser(National Center for Tumor Diseases), Christian Thiede(National Center for Tumor Diseases)
Cited by 354
Abstract
Related Papers
No related papers found
Powered by citation graph analysis